Investors

Talaris Therapeutics is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation that it believes has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. After demonstrating robust phase 2 clinical results, Talaris’ lead product candidate, FCR001, and its proprietary therapeutic approach, Facilitated Allo-HSCT Therapy, are currently being assessed in phase 3 clinical trials. Talaris has a cell manufacturing and research location in Louisville, KY and corporate headquarters in Boston, MA.